Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ZEVRA THERAPEUTICS, INC.
Report date December 31, 2025 · Filed January 07, 2026
Section 16 reporting ended · disclosed 2026-01-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 143,515 |
Ending reported balance
After 2025-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-31 · Exercise / conversion · Acquired 140,667 · Balance 192,028 F1: Shares issued upon vesting of restricted stock units and performance stock units on December 31, 2025. Row 2 · 2025-12-31 · Tax withholding · Disposed 48,513 · Balance 143,515 F2: Shares withheld to cover withholding taxes for the vested restricted stock units and performance stock units. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-12-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-31 · Exercise / conversion · Disposed 86,667 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-12-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-31 · Exercise / conversion · Disposed 34,000 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025. |
| Performance Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-12-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-31 · Exercise / conversion · Disposed 20,000 · Balance 0 F5: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares issued upon vesting of restricted stock units and performance stock units on December 31, 2025.
F2: Shares withheld to cover withholding taxes for the vested restricted stock units and performance stock units.
F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F4: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025.
F5: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2025 Filed Jan 7, 2026 16:18 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionPerformance Stock Unit · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001488774-26-000002 · wk-form4_1767820678.xml · derivative · entry 5 Clifton R. LaDuane · CIK 0001488774 · Former CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025. F4 · derivative.expiration_date: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025. Read SEC document |
| December 31, 2025 Filed Jan 7, 2026 16:18 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001488774-26-000002 · wk-form4_1767820678.xml · derivative · entry 4 Clifton R. LaDuane · CIK 0001488774 · Former CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025. F4 · derivative.expiration_date: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025. Read SEC document |
| December 31, 2025 Filed Jan 7, 2026 16:18 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 86,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001488774-26-000002 · wk-form4_1767820678.xml · derivative · entry 3 Clifton R. LaDuane · CIK 0001488774 · Former CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 86,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025. F4 · derivative.expiration_date: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025. Read SEC document |
| December 31, 2025 Filed Jan 7, 2026 16:18 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Tax withholdingCommon Stock | 48,513 | $8.96 | $434,676.48 |
DisclosureSEC source: 0001488774-26-000002 · wk-form4_1767820678.xml · nonDerivative · entry 2 Clifton R. LaDuane · CIK 0001488774 · Former CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,515 F2 · shares: Shares withheld to cover withholding taxes for the vested restricted stock units and performance stock units. Read SEC document |
| December 31, 2025 Filed Jan 7, 2026 16:18 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 140,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001488774-26-000002 · wk-form4_1767820678.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · Former CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon vesting of restricted stock units and performance stock units on December 31, 2025. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 17:55 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 11,000 | $7.86 | $86,471.00 |
DisclosureSEC source: 0001437749-25-004068 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO & Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,361 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 10/15/2024 Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 17:20 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 43,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002625 · rdgdoc.xml · derivative · entry 2 Clifton R. LaDuane · CIK 0001488774 · CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,667 Underlying: Common Stock · 43,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The first tranche of the restricted stock units vested and settled on January 31, 2025, and the remaining two tranches of the restricted stock units will vest and settle inequal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. F2 · derivative.expiration_date: The first tranche of the restricted stock units vested and settled on January 31, 2025, and the remaining two tranches of the restricted stock units will vest and settle inequal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 17:20 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 43,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-002625 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 17:20 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002625 · rdgdoc.xml · derivative · entry 4 Clifton R. LaDuane · CIK 0001488774 · CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 30, 2026, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's continued service through such vesting date. F4 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 30, 2026, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's continued service through such vesting date. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 17:20 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 68,000 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0001437749-25-002625 · rdgdoc.xml · derivative · entry 3 Clifton R. LaDuane · CIK 0001488774 · CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2035-01-29 F3 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| July 17, 2024 Filed Jul 17, 2024 17:54 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 2,000 | $6.77 | $13,540.00 |
DisclosureSEC source: 0001437749-24-022939 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,469 Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 20:11 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 130,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-003024 · rdgdoc.xml · derivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Grant to the Reporting Person of restricted stock units ("RSU"). F2 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment. F2 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment. Read SEC document |
| September 06, 2023 Filed Sep 6, 2023 17:11 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 1,000 | $4.96 | $4,959.10 |
DisclosureSEC source: 0001437749-23-025317 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,309 Read SEC document |
| May 18, 2023 Filed May 18, 2023 16:56 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 689 | $4.95 | $3,410.21 |
DisclosureSEC source: 0001437749-23-015140 · rdgdoc.xml · nonDerivative · entry 3 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,742 Read SEC document |
| May 18, 2023 Filed May 18, 2023 16:56 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 2,000 | $4.95 | $9,899.80 |
DisclosureSEC source: 0001437749-23-015140 · rdgdoc.xml · nonDerivative · entry 2 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,053 Read SEC document |
| May 18, 2023 Filed May 18, 2023 16:56 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 51 | $4.94 | $251.94 |
DisclosureSEC source: 0001437749-23-015140 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,053 Read SEC document |
| March 10, 2023 Filed Mar 13, 2023 07:56 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 1,725 | $4.15 | $7,158.75 |
DisclosureSEC source: 0001437749-23-006277 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,002 Read SEC document |
| January 13, 2023 Filed Jan 13, 2023 17:28 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 25 | $5.59 | $139.63 |
DisclosureSEC source: 0001437749-23-001060 · rdgdoc.xml · nonDerivative · entry 2 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,277 Read SEC document |
| January 13, 2023 Filed Jan 13, 2023 17:28 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 610 | $5.82 | $3,550.20 |
DisclosureSEC source: 0001437749-23-001060 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,252 Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:57 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 459,726 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001437749-23-000919 · rdgdoc.xml · derivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,726 Underlying: Common Stock · 459,726 shares Expires 2033-01-08 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 6, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 19:57 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 400 | $5.98 | $2,393.20 |
DisclosureSEC source: 0001437749-22-023512 · rdgdoc.xml · nonDerivative · entry 2 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,109 Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 19:57 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 600 | $5.98 | $3,588.00 |
DisclosureSEC source: 0001437749-22-023512 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,709 Read SEC document |
| May 18, 2022 Filed May 18, 2022 17:17 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 1,200 | $5.00 | $5,999.04 |
DisclosureSEC source: 0001437749-22-012932 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,440 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 17:15 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 83,486 | $0.00 Strike: $7.17 | $0.00 |
DisclosureSEC source: 0001437749-22-002399 · rdgdoc.xml · derivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,486 Underlying: Common Stock · 83,486 shares Expires 2032-01-31 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on February 1, 2023 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 16:57 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 510 | $8.29 | $4,227.90 |
DisclosureSEC source: 0001437749-21-027098 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,240 Read SEC document |
| September 29, 2021 Filed Sep 29, 2021 16:10 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 215 | $9.38 | $2,016.70 |
DisclosureSEC source: 0001437749-21-022841 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,730 Read SEC document |
| September 20, 2021 Filed Sep 20, 2021 17:03 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 935 | $8.59 | $8,028.38 |
DisclosureSEC source: 0001437749-21-022431 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,515 Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 16:04 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 230 | $9.11 | $2,094.15 |
DisclosureSEC source: 0001437749-21-021308 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,580 Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 16:49 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 82,423 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001437749-21-020862 · rdgdoc.xml · derivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,423 Underlying: Common Stock · 82,423 shares Expires 2031-08-19 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on August 20, 2022 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 16:22 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 75 | $14.11 | $1,058.25 |
DisclosureSEC source: 0001437749-21-015562 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,350 Read SEC document |
| May 27, 2021 Filed May 27, 2021 17:50 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 150 | $9.85 | $1,477.50 |
DisclosureSEC source: 0001437749-21-013577 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,275 Read SEC document |
| August 26, 2020 Filed Aug 26, 2020 17:08 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 1,000 | $0.84 | $839.00 |
DisclosureSEC source: 0001437749-20-018766 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 16:48 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 2,000 | $0.70 | $1,390.00 |
DisclosureSEC source: 0001437749-20-018274 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,000 Read SEC document |
| June 11, 2020 Filed Jun 11, 2020 16:10 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 1,500 | $0.19 | $288.45 |
DisclosureSEC source: 0001437749-20-012894 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Read SEC document |
| May 26, 2020 Filed May 26, 2020 16:29 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 11,500 | $0.18 | $2,104.50 |
DisclosureSEC source: 0001437749-20-011741 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Read SEC document |
| March 25, 2020 Filed Mar 25, 2020 17:37 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 1,000 | $0.22 | $218.20 |
DisclosureSEC source: 0001437749-20-006118 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 16:28 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 8,000 | $0.25 | $2,010.40 |
DisclosureSEC source: 0001437749-20-004949 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:38 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001437749-20-002097 · rdgdoc.xml · derivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2030-02-04 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 50% of the shares underlying the option will vest upon the approval by the U.S. Food and Drug Administration of a new drug application for the Company's product candidate, KP415. The remaining 50% of the shares underlying the option will vest upon the approval of a label for KP415 which includes 30 minute onset and 13-hour duration (the "30/13 Label") as defined in the KP415 License Agreement dated September 3, 2019. Each vesting event is contingent upon such optionee's continued employment with the Issuer at the relevant vesting date as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| December 27, 2019 Filed Dec 30, 2019 16:26 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 2,250 | $0.42 | $937.58 |
DisclosureSEC source: 0001437749-19-025002 · rdgdoc.xml · nonDerivative · entry 3 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| December 27, 2019 Filed Dec 30, 2019 16:26 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 5,000 | $0.42 | $2,087.50 |
DisclosureSEC source: 0001437749-19-025002 · rdgdoc.xml · nonDerivative · entry 2 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,750 Read SEC document |
| December 27, 2019 Filed Dec 30, 2019 16:26 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 5,000 | $0.42 | $2,084.50 |
DisclosureSEC source: 0001437749-19-025002 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,750 Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 16:15 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001437749-19-023642 · rdgdoc.xml · derivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2029-11-24 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 100% of the shares underlying the option will vest upon the acceptance of a new drug application for the Company's product candidate, KP415, by the U.S. Food and Drug Administration, provided that at the relevant vesting date such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| September 25, 2019 Filed Sep 25, 2019 20:58 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 3,650 | $0.75 | $2,719.98 |
DisclosureSEC source: 0001437749-19-019061 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,750 Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 16:59 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 4,900 | $0.89 | $4,339.44 |
DisclosureSEC source: 0001437749-19-018489 · rdgdoc.xml · nonDerivative · entry 2 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 16:59 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 100 | $0.86 | $86.00 |
DisclosureSEC source: 0001437749-19-018489 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,200 Read SEC document |
| September 11, 2019 Filed Sep 11, 2019 16:50 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 500 | $0.95 | $472.60 |
DisclosureSEC source: 0001437749-19-018218 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,100 Read SEC document |
| September 06, 2019 Filed Sep 6, 2019 17:06 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 850 | $0.77 | $652.29 |
DisclosureSEC source: 0001437749-19-018003 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 17:36 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001437749-19-002169 · rdgdoc.xml · derivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2029-02-05 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on February 6, 2020 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| October 11, 2018 Filed Oct 11, 2018 18:52 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 650 | $2.54 | $1,651.91 |
DisclosureSEC source: 0001437749-18-018208 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 16:14 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 525 | $6.10 | $3,202.50 |
DisclosureSEC source: 0001437749-18-011084 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.